BioSpace News Archive

Patients treated with Opdivo plus Yervoy with two cycles of chemotherapy showed sustained improvements in overall survival and progression-free survival and increased duration of response vs. chemotherapy at two years

Gilead Sciences, Inc. and Kite, a Gilead Company, announced that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021.

New efficacy, safety and pharmacokinetic data in first six subjects to be presented in poster session at 2021 ASCO Annual Meeting At 90 days after transplant, measurable residual disease (MRD) as measured by cytogenetics, flow cytometry and next-generation sequencing was negative (undetected) in five patients and reduced in one patient

Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma First presentation of Phase 3 data from a trial evaluating a LAG-3-blocking antibody

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced interim results from the Phase III IMpower010 study

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that additional data from its Phase 1/2a study of PBCAR0191, will be presented at the 2021 American Society of Clinical Oncology (ASCO) Meeting being held virtually June 4-8, 2021.

AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA ® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma - Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS Relative to Sorafenib Continues to Improve with Longer Follow-up -

AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC – Study Achieved Primary Endpoint of mPFS in Patients Treated with Ficlatuzumab/Cetuximab (ERBITUX ® ) Combination – – 38% ORR, Including 13% CRs and 25% PRs, and Median PFS of 4.1 months Observed in HPV Negative Patients Treated with Ficlatuzumab/Cetuximab Combination –

Results Demonstrate KD033 was Well Tolerated in All Patients through Initial Dose Cohorts, Allowing for Continuation of Dose Escalation

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, is presenting updated results of their first-in-human multicenter study of GC012F for the treatment of multiple myeloma